EU market entry is a commercial decision with regulatory constraints. Not the other way around.
A structured approach that starts with commercial viability. Regulatory strategy follows. For pharmaceutical manufacturers ready to enter Europe with clarity, not guesswork.
Request an assessmentMost failed EU entries share one pattern. The regulatory strategy is built without a commercial thesis.
Companies file into markets with no pricing clarity, no distributor alignment, and no revenue path. The regulatory pathway only matters once the commercial strategy is defined.
In the majority of cases we review, the first chosen EU country is wrong. A registration you cannot monetize is not a regulatory success. It is a negative ROI event.
Where companies lose time and capital
Countries chosen by size, not by reimbursement speed or competitive density. Most DCP strategies fail from distributor misalignment before they fail from regulation.
Filing without confirmed distribution or pricing viability. The typical deviation: 12–18 months of delay before a single unit is sold.
CTD deficiencies found during regulatory review, not before submission. Remediation at this stage doubles cost and resets timelines.
Relying on a single CRO without distributor relationships, local qualified persons, or a compliant supply chain ready for EU requirements.
Production sites that do not meet EU GMP inspection standards. Discovered post-submission, these gaps add 6–12 months to every timeline.
Typical cost of a misaligned EU entry: €300k–€500k in direct spend, plus 18–24 months lost.
The EU remains one of the most commercially attractive pharmaceutical markets globally
Products registered in Europe command higher pricing in the Middle East, Latin America, and parts of Asia. EU entry is a strategic lever, not just a market.
We reverse the typical EU entry sequence. Most companies start with regulatory. We start with commercial viability.
Market sizing, pricing feasibility, distribution access, competitive landscape, patent and exclusivity constraints. The business case comes before the dossier. Capital is not committed to markets that cannot deliver returns.
Regulatory route selected to support the commercial strategy, not the other way around. Manufacturing compliance assessed in parallel. All critical blockers identified before submission.
Dossier readiness, partner selection, timelines, and cost. A clear go/no-go decision before significant investment is committed.
Most companies treat regulatory, commercial, and compliance as separate workstreams. We align them from day one.
Core engagement: 2–3 weeks
You receive a strategic document with a clear recommendation. Not a slide deck of general advice.
Regulatory pathway with commercial rationale. Country prioritization ranked by pricing, competition, and market access.
Dossier readiness review and cost to close gaps. Manufacturing and compliance considerations for EU requirements.
IP barriers, SPC exposure, and launch timing constraints mapped against your target markets.
Steps, timelines, costs, and partners. Risk map with mitigation strategies. Go/no-go recommendation before major investment.
Two phases, clearly scoped
- Commercial viability assessment
- Regulatory pathway selection
- Manufacturing & compliance review
- Patent & exclusivity landscape
- Country prioritization
- Execution roadmap
- Go / no-go recommendation
- Full dossier development
- Manufacturing compliance consulting
- Regulatory submission management
- Commercial partner identification
- Patent landscaping & FTO analysis
- Market entry execution support
Decision protection. If EU entry is not viable, you avoid €300k–€500k in wasted investment and 12–24 months of misdirected effort. This engagement prevents incorrect decisions, not just supports correct ones.
This is not a regulatory-only engagement
- Regulatory feasibility report only
- No commercial viability assessment
- No patent or exclusivity review
- No partner network or introductions
- Delivered over 2–3 months
- Regulatory + commercial strategy integrated
- Patent & exclusivity landscape included
- Introductions to vetted EU partners
- Core package delivered in 2–3 weeks
- Execution-ready output
We do not take on projects where EU entry is unlikely to succeed.
If you are considering EU market entry, we can provide an initial assessment within one week.
No commitment required. We start with a focused conversation about your product, your timeline, and your commercial objectives. If EU entry makes sense, we outline the path. If it does not, we tell you directly.